- Bayer Schering Pharma
Infobox Company
company_name = Bayer Schering PharmaAG
company_
company_type =Subsidiary
foundation =1851 "Schering"2006 "merged"
location = Berlin-Wedding,Germany
key_people = Hubertus Erlen, CEO
num_employees = 26,000 (2004)
revenue = € 10.267 billion (2007)
industry =Pharmaceutical
owner =Bayer
products =Gynaecology &Andrology
Special therapeutics
Diagnostical devices &Nuclear medicine
Oncology
homepage = [http://www.bayerscheringpharma.de/ www.bayerscheringpharma.de]Bayer Schering Pharma AG is a research-centered
pharmaceutical company that was formed by the merger ofSchering withBayer onDecember 29 2006 . The company was originally founded in1851 byErnst Schering (1824-1889). The company employs more than 26,000 people in 140 subsidiaries all over the world. The company's headquarters are in Berlin-Wedding,Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion (2003). They retain the largest German manufacturing facility which is located inBergkamen .The company focuses on the business areas ofgynaecology &andrology ,oncology and also special therapeutics, diagnostical devices &nuclear medicine . Schering best-known product is their line ofcombined oral contraceptive pill s.Through Bayer Healthcare AG Bayer Schering Pharma is a full member of the
European Federation of Pharmaceutical Industries and Associations (EFPIA). [cite news|url=http://www.efpia.eu/content/default.asp?PageID=559&DocID=4883|title=The Pharmaceutical Industry in Figures - 2008 Edition |publisher=European Federation of Pharmaceutical Industries and Associations (EFPIA)|pages=49|language=english|accessdate=2008-08-25]Collaborative Research
In addition to internal research and development activities Bayer Schering Pharma is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the
InnoMed PredTox . [Mattes WB (2008), Public consortium efforts in toxicogenomics, Methods Mol Biol. 2008;460:221-38 [http://www.ncbi.nlm.nih.gov/pubmed/18449490] ] cite web|url=http://www.innomed-predtox.com/consortium/members/|title=InnoMed PredTox Member Organizations|accessdate=2008-08-25] The company is expanding its activities in joint research projects within the framework of theInnovative Medicines Initiative ofEFPIA and theEuropean Commission .cite web|url=http://imi.europa.eu/docs/calls01_en.zip|title=IMI Call Topics 2008|last=Innovative Medicines Initiative|work=IMI-GB-018v2-24042008-CallTopics.pdf|publisher=European Commission|accessdate=2008-08-25]Bayer's Takeover Bid
On
March 13 ,2006 ,Merck KGaA announced a €14.6bn bid for Schering [http://inter-x.info/en/web/index.html] . The offer document was due to be issued in early April 2006.Merck's takeover bid was surpassed by
Bayer 's $19.5B white-knight bid for Schering on March 23, 2006. In June 2006 Bayer finally bought the majority of shares, over 96%. A domination agreement using the code name "Step One" was used for the take-over. OnFebruary 17 2007 the company publicly announced that 1,000 jobs would be cut throughvoluntary redundancy from the Berlin operations with effect until March 2008.References
External links
Wikimedia Foundation. 2010.